PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16094929

Overactive bladder.

Rajesh Kavia·Faiz Mumtaz
View original source ↗Export metadata ↓

Abstract

Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of local pathological or hormonal factors. It is a common complaint of men and women alike, with estimates of 22 million sufferers. ApproximateLy 70% of men with bladder outflow obstruction will have some symptoms of OAB. The exact pathophysiology of OAB in bladder outflow obstruction is yet to be elucidated; evidence to date points to changes in both the efferent and afferent innervation and the detrusor. Management of OAB can be is generally with pharmacological agents such as anticholinergics or operative measures such as the 'Clam' cystoplasty. More recent treatment modalities include intravesicaL oxybutynin, intradetrusor botulinum toxin and neuromodulation. More specific treatment options for OAB in bladder outflow obstruction include relief of the obstruction with surgical (e.g. transurethraL resection of prostate) or pharmaceutical (e.g. a blockers) methods.

Explore related subjects

Anti-Dyskinesia AgentsBehavior TherapyElectric StimulationHumansMuscarinic AntagonistsMuscle Relaxants, CentralUrinary Bladder DiseasesUrinary IncontinenceUrologic Surgical ProceduresJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rajesh Kavia, Faiz Mumtaz. 2005. Overactive bladder.. https://doi.org/10.1177/146642400512500411

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

European consensus table 2006 on botulinum toxin for children with cerebral palsy.

An interdisciplinary group of experienced botulinum toxin users and experts in the field of movement disorders was assembled, to develop a consensus on best practice for the treatment of cerebral palsy using a problem-orientated approach to integrate theories and methods. The authors tabulated the supporting evidence to produce a condensed but comprehensive information base, pooling data and experience from nine European countries, 13 institutions and more than 5500 patients. The consensus table summarises the current understanding regarding botulinum toxin treatment options in children with CP.

Anti-Dyskinesia Agents↗
PubMed2006

Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia.

BACKGROUND: Achalasia is an oesophageal motility disorder, of unknown cause, which results in increased lower oesophageal sphincter (LOS) tone and symptoms of difficulty swallowing. Treatments are aimed at reducing the LOS tone. Current endoscopic therapeutic options include pneumatic dilation (PD) or botulinum toxin injection (BTX). OBJECTIVES: The objective of this review was to compare the efficacy and safety of two endoscopic treatments, pneumatic dilatation and intrasphincteric botulinum toxin injection, in the treatment of oesophageal achalasia. SEARCH STRATEGY: We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group trials register, the Cochrane Central Register of Controlled Trials, MEDLINE (1966 to Oct 2005), EMBASE (1980 to Oct 2005), BIOSIS (1969 to Oct 2005) and Web of Science (1955 to October 2005). We also searched abstracts from significant Gastroenterology meetings (DDW, UEGW) and reference lists of articles. SELECTION CRITERIA: Randomised controlled trials comparing PD to BTX injection in patients with primary achalasia. DATA COLLECTION AND ANALYSIS: Two review authors independently performed quality assessment and data extraction. MAIN RESULTS: Six studies involving 178 participants were included. Two studies were excluded from the meta-analysis of remission rates on the basis of clinical heterogeneity of the initial endoscopic protocols. There was no significant difference in remission between PD or BTX treatment within four weeks of the initial intervention, with a relative risk of remission of 1.15 (95% CI 0.95 to 1.38, P = 0.39) for PD compared to BTX. There was also no significant difference in the mean oesophageal pressures between the treatment groups; weighted mean difference for PD of -0.77 (95% CI -2.44 to 0.91, P = 0.37). Data on remission rates following the initial endoscopic treatment was available for two studies at six months and three studies at 12 months. At six months 22 of 29 PD participants were in remission compared to 7 of 27 in the BTX group, giving a relative risk of 2.90 (95% CI 1.48 to 5.67, P = 0.002); whilst at 12 months 33 of 47 PD participants were in remission compared to 11 of 43 BTX participants, relative risk of 2.67 (95% CI 1.58 to 4.52, P = 0.0002). No serious adverse outcomes occurred in participants receiving BTX, whilst PD was complicated by perforation in three cases. AUTHORS' CONCLUSIONS: The results of this meta-analysis would suggest that PD is the more effective endoscopic treatment in the long term (greater than six months) for patients with achalasia.

Anti-Dyskinesia Agents↗